Drug Profile
DCVAC/OvCa
Alternative Names: Dendritic cell vaccine/Ovarian cancer - SotioLatest Information Update: 03 Jan 2022
Price :
$50
*
At a glance
- Originator SOTIO
- Developer Peking University; SOTIO
- Class Antineoplastics; Cancer vaccines; Cell therapies; Dendritic cell vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Most Recent Events
- 31 Aug 2021 SOTIO withdraws the phase III VITALIA trial in Fallopian tube cancer, Peritoneal cancer and relapsed Ovarian cancer (Late-stage disease)
- 04 Jun 2021 Updated efficacy and safety data from the phase II SOV01 trial in Ovarian cancer presented at the 57th Annual Meeting of the American Society of Clinical Oncology (ASCO-2021)
- 23 Mar 2021 Phase-II clinical trials in Fallopian tube cancer (First-line therapy, Late-stage disease, Adjuvant therapy) in China (SC) (NCT04834544)